We examined the correlation between clinicopathological features and serum lipid control of 120 postmenopausal patients with HR-positive/HER2-negative breast cancer treated for dyslipidaemia (Supplement Fig. S7) (Table 2). This evidence concerns the gene ERBB2 and breast cancer.